The administrative core is responsible for the operation of the program and supervision of the conduct of the proposed grant. The core facilitates communication between investigators and visits of outside investigators to MD Anderson Cancer Center. The core maintains the central databases for the clinical and translational research described in the projects as well as the GMP - Immune Assessment Core (Core E). The core supports the FDA IND submissions and reporting required for protocols in the POI. The core manages program personnel and budgets for each section ofthe grant. The core is responsible for preparing reports for the research projects and publications. The CML group meets multiple times per week in meeting related to leukemias, stem cell transplantation and specific laboratory research related to this program. We discuss the design, status and results of clinical and laboratory research, sample acquisition, status of patients participating on clinical research studies, pathology, cytogenetic, molecular analysis review. This includes a weekly CML POI program meetings and broader meetings involving the Leukemia, Stem Cell Transplant and Cellular Therapy (SCTCT) and Molecular Pathology programs. Specifically, the Administrative Core has the following objectives to accomplish: ? Provide leadership to and oversight of the cores and research projects ofthe Program. ? Convene all necessary meetings, including meetings ofthe External Scientific Advisory Board, regularly scheduled meetings of the investigators, and discussion of all the clinical trials in the program. ? Prepare grant continuation submissions for the NCI and to comply with internal reporting requirements. ? Coordinate data quality control and quality assurance in conjunction with the Biostatistics and other projects and cores. ? Monitor and control expenditures and maintain budget information. ? Track and maintain record of all publications, including abstracts and manuscripts, resulting from the program project.
The administrative core oversees this CML program project grant under the leadership of Dr. Champlin. Core A monitors the progress from each project and core and ensure the proper use of funding. Core A also supervises the conduct of clinical research and ascertain the regulatory compliance and HIPAA regulations are followed.
|Eiring, A M; Page, B D G; Kraft, I L et al. (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29:586-97|
|Zhang, Weiguo; Gao, Chen; Konopleva, Marina et al. (2014) Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res 20:2363-74|
|Tao, Wenjing; Leng, Xiaohong; Chakraborty, Sandip N et al. (2014) c-Abl activates janus kinase 2 in normal hematopoietic cells. J Biol Chem 289:21463-72|
|Thall, Peter F; Nguyen, Hoang Q; Zohar, Sarah et al. (2014) Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. J Am Stat Assoc 109:931-943|
|Mak, P Y; Mak, D H; Mu, H et al. (2014) Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis 19:698-707|
|Jin, Ick Hoon; Liu, Suyu; Thall, Peter F et al. (2014) Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. J Am Stat Assoc 109:525-536|
|Benjamini, Ohad; Kantarjian, Hagop; Rios, Mary Beth et al. (2014) Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma 55:2879-86|
|Havelange, Violaine; Ranganathan, Parvathi; Geyer, Susan et al. (2014) Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood 123:2412-5|
|Ohanian, Maro; Kantarjian, Hagop M; Quintas-Cardama, Alfonso et al. (2014) Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 14:155-162.e1|
|Zabriskie, Matthew S; Eide, Christopher A; Tantravahi, Srinivas K et al. (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:428-42|
Showing the most recent 10 out of 220 publications